Immunic (IMUX) Stock
Small biotech company developing immune system treatments. Here's the price, business snapshot, and what's worth knowing about Immunic in October 2026.
Immunic Inc (IMUX) is a small-cap biotechnology company with a market capitalisation of about $81.12 million. As a company in the biotech space, its prospects tend to be driven by clinical results, regulatory decisions, partnerships and financing activity rather than steady earnings. That makes IMUX inherently more speculative and often more volatile than larger, diversified firms. Investors should focus on the company’s latest regulatory filings, press releases and cash runway, since small biotechs frequently need to raise capital to fund development. Potential upside may come from positive trial readouts or strategic collaborations, while downside risks include trial failures, regulatory setbacks and dilution from new funding. This summary is educational only; it is not personal financial advice. Consider your risk tolerance and consult an authorised financial professional before making investment decisions.
Immunic (IMUX) Stock Forecast
Analyst price target, next 12 months
$27.95
+251.2% vs today's $7.96
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Immunic have a consensus 12-month target of $27.95, above the current price of $7.96.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 2 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immunic Inc.'s stock with a target price of $27.95, indicating strong growth potential.
Financial Health
Immunic Inc. is demonstrating solid cash flow and a strong book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Potential Growth Drivers
Clinical readouts, approvals or partnerships can materially change outlook, though these events are uncertain and can go either way.
Catalysts To Watch
Upcoming trial milestones or financing announcements are common catalysts; they may boost momentum or increase volatility.
Market & Funding Context
Small-cap biotechs often need fresh capital to progress programmes — check cash runway and dilution risk before investing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
